论文部分内容阅读
目的观察替吉奥联合三维适形放疗治疗局部晚期直肠癌的疗效及安全性。方法对60例具有可测量指标的局部晚期直肠癌患者给予三维适形放疗,同步口服化疗,其中口服替吉奥组30例,采用替吉奥胶囊80 mg/(m2.d),口服,2次/d,连续服用2周,休息1周,为1个周期;口服希罗达组30例,希罗达2000 mg/(m2.d),口服,2次/d,连续服用2周,休息1周,为1个周期。每例患者至少进行2个周期的治疗,结束后进行评价。结果替吉奥组和希罗达组有效率(CR+PR)分别为86.7%和89.7%,差异无统计学意义(P>0.05),而替吉奥组手足综合征的发生率明显低于希罗达组(P<0.01),胃肠道反应、白细胞下降、放射性直肠炎等不良反应未见明显差异。结论替吉奥联合三维适形放疗治疗局部晚期直肠癌安全有效,值得临床推广应用。
Objective To observe the efficacy and safety of TIGO combined with three-dimensional conformal radiotherapy in the treatment of locally advanced rectal cancer. Methods Sixty patients with locally advanced rectal cancer with measurable index were treated with three-dimensional conformal radiotherapy and concurrent oral chemotherapy. Among them, 30 patients were treated with TIGO, 80 mg / (m2.d) for oral administration, 2 Times daily for 2 weeks, rest for 1 week for 1 cycle; oral Xeloda 30 cases, Xeloda 2000 mg / (m2.d), orally, 2 times / d, taking 2 consecutive weeks, 1 week off for 1 cycle. Each patient is treated for at least 2 cycles and then evaluated. Results The effective rates (CR + PR) were 86.7% and 89.7% for the group of Teglitazar and Xeloda, respectively, with no significant difference (P> 0.05), while the incidence of hand-foot syndrome was significantly lower in the group of Tegi Rhoda group (P <0.01), gastrointestinal reactions, leukopenia, radiation proctitis and other adverse reactions no significant difference. Conclusion The combination of three-dimensional conformal radiotherapy for the treatment of locally advanced rectal cancer is safe and effective, which is worthy of clinical application.